Journal article icon

Journal article

SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants

Abstract:

SB 9200 is a novel, first-in-class oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus, and influenza and has demonstrated activity against hepatitis B virus (HBV) in vitro and in vivo. In phase I clinical trials in chronically infected HCV patients, SB 9200 has been shown to reduce HCV RNA by up to...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1002/jmv.24809

Authors


More by this author
Role:
Author
ORCID:
0000-0001-9158-2971
More by this author
Role:
Author
ORCID:
0000-0003-2617-9523
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Target Discovery Institute
Role:
Author
ORCID:
0000-0002-2354-3281
More from this funder
Name:
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Grant:
R01 AI094469
Publisher:
Wiley
Journal:
Journal of Medical Virology More from this journal
Volume:
89
Issue:
9
Pages:
1620-1628
Publication date:
2017-03-17
Acceptance date:
2017-02-24
DOI:
ISSN:
0146-6615 and 1096-9071
Pmid:
28303593
Language:
English
Keywords:
Pubs id:
pubs:1003682
UUID:
uuid:69124fe4-5f5a-451f-9396-f9b044c4fba9
Local pid:
pubs:1003682
Source identifiers:
1003682
Deposit date:
2019-10-24

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP